NAGE Q3 2021 Earnings — Niagen Bioscience Inc Revenue & Financial Results | Market Cap Arena

NAGENiagen Bioscience Inc

$393M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17M+22.1% YoY

Gross Profit

$11M61.1% margin

Operating Income

-$9M-51.1% margin

Net Income

-$9M-51.2% margin

EPS (Diluted)

$-0.13

QoQ Revenue Growth

-2.2%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$60M

Total Liabilities

$25M

Stockholders' Equity

$35M

Cash & Equivalents

$33M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17M	$14M	+22.1%
Gross Profit	$11M	$8M	+25.1%
Operating Income	-$9M	-$4M	-110.7%
Net Income	-$9M	-$4M	-110.1%